Refractory Infantile Spasms clinical trials at University of California Health
1 research study open to eligible people
open to eligible people ages 6 months to 36 months
This open label, multicenter study allows JBPOS0101 (investigational product) to be given as either add-on therapy or monotherapy for patients with refractory infantile spasms. The design and choice of study population of this Phase 2 clinical study is based on the need to provide initial safety, tolerability, pharmacokinetics (PK), and efficacy outcomes of the investigational product for future clinical studies.
at UCLA UCSF